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Recent early stage clinical trials evaluating the adoptive transfer of patient CD8+ T-cells re-
directed with antigen receptors recognizing tumors have shown very encouraging results.
These reports provide strong support for further development of the therapeutic con-
cept as a curative cancer treatment. In this respect combining the adoptive transfer of
tumor-specific T-cells with therapies that increase their anti-tumor capacity is viewed as a
promising strategy to improve treatment outcome. The ex vivo genetic engineering step
that underliesT-cell re-direction offers a unique angle to combine antigen receptor delivery
with the targeting of cell-intrinsic pathways that restrict T-cell effector functions. Recent
progress in genome editing technologies such as protein- and RNA-guided endonucleases
raise the possibility of disrupting gene expression in T-cells in order to enhance effec-
tor functions or to bypass tumor immune suppression. This approach would avoid the
systemic administration of compounds that disrupt immune homeostasis, potentially avoid-
ing autoimmune adverse effects, and could improve the efficacy of T-cell based adoptive
therapies.
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INTRODUCTION
Although there is still controversy over the role of the immune
system in protecting the organism against the development of
neoplasms in a natural setting (1) it is well accepted that artificial
immunity can efficiently contain and even eradicate established
tumors (2). Harnessing the anti-tumor potential of T-cells, and
particularly CD8+ T-cells, is a promising approach for curative
cancer treatment. Because of their relative ease of administration
and documented low toxicities therapeutic vaccines that trigger
T-cell responses are a very attractive approach. However, even
though they efficiently induce antigen-specific immunity, the clin-
ical benefit of cancer vaccines has so far been limited (3). In
contrast adoptive cell therapies (ACT), where T-cells are modified
ex vivo and re-infused in a patient’s circulation, are more difficult
to implement and require important infrastructural investment.
Yet a number of studies have now reported long-term remissions
or tumor clearance (4–6), warranting further development of the
therapeutic concept.
While conferring the immune system with the ability to recog-
nize tumors through vaccination or ACT is a pre-requisite for the
induction of efficient anti-tumor responses it is likely insufficient
to achieve long-term clinical benefit in a majority of patients. An
increasing body of evidence points to the necessity of combining
different therapeutic approaches in order to improve treatment
outcome (7, 8). For instance several small-molecule compounds
that target oncogenic pathways also enhance tumor destruction
by immune mechanisms, e.g., by sensitizing cancer cells to cytol-
ysis (9, 10). The coordinated delivery of these compounds with
immunotherapies is expected to improve clinical responses in an
additive or even synergistic manner. Similarly the combination of
immune-based therapies also holds great potential. Monoclonal
antibodies (mAbs) blocking immune checkpoint receptors have
recently emerged as promising therapeutics and many believe
that the recent marketing authorization of Ipilimumab, target-
ing CTLA-4, heralds great strides in this area. Immune checkpoint
receptor blocking agents are currently marketed or developed as
single therapies but are expected to achieve maximal efficacy in
combination with immune stimulatory approaches such as vacci-
nation or ACTs (11, 12). Although generic treatment combinations
will undoubtedly provide some degree of clinical benefit it is the
prospect of developing personalized therapies tailored to individ-
ual needs that holds the greatest potential to improve clinical out-
come in cancer therapy. The heterogenous nature of similar tumor
histologies as well as individual genetic variability are believed
to account for the varied response levels to generic treatments
and the wider availability of prognostic tools should help define
adequate treatment options that improve patient response. With
respect to cancer vaccines or ACTs information about the nature
of the immune checkpoint pathway(s) relevant to a tumor would
be particularly useful in order to counteract immune suppression.
T-cell-based ACTs rely on the infusion in a patient’s circula-
tion of ex vivo expanded tumor-infiltrating lymphocytes (TILs)
or peripheral blood T-cells transduced with viral vectors express-
ing a tumor-specific antigen receptor. This engineering step offers
the opportunity to transfer additional genetic material conferring
T-cells with enhanced anti-tumor activity. Targeted genome edit-
ing relying on viral gene transfer could readily be combined with
the delivery of antigen receptors at little additional cost in one
unique therapeutic entity. This approach would avoid the draw-
backs associated with combining treatment modalities of different
nature requiring distinct administration regimens, e.g., cellular
therapy and mAb injection. In addition cell-intrinsic disruption
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of immune checkpoints in tumor-specific T-cells is likely to display
a better safety profile than the systemic administration of block-
ing agents. Recently developed gene targeting technologies such
as zinc-finger proteins (ZFPs), transcription activator-like pro-
teins (TALs), and RNA-guided endonucleases (RGENs) could thus
be harnessed in order to silence the expression of T-cell-intrinsic
genes that restrain their anti-tumor potential.
MAIN TEXT
TECHNICAL ASPECTS AND CHALLENGES TO THE MODULATION OF
GENE EXPRESSION IN T-CELLS
RNA interference (RNAi) often is the technique of choice to silence
gene expression in somatic cells and lentivirus-mediated RNAi is a
good option for sustained and efficient silencing. Most lentivi-
ral RNAi systems express short-hairpin RNAs (shRNAs) from
RNApolIII promoters, which drive high levels of transcription
using precise initiation and termination sites. A recurrent problem
of lentivirus-mediated RNAi, which is particularly salient in T-cells
(13), is that the constant generation of shRNAs interferes with
endogenous miRNA biogenesis and can result in the deregulation
of gene expression (14, 15). This issue has prompted investigators
to seek alternative methods to silence gene expression (16).
Recently developed genome editing technologies based on
DNA-targeting proteins have the potential to revolutionize ACTs
by offering convenient tools to alter gene expression. TAL
effector-nucleases (TALENs) and ZFP-nucleases (ZFNs) effect
complete gene knockout (Figure 1A) and are promising alter-
natives to RNAi for therapeutic applications (17–19). TALs are
bacterial DNA-binding proteins consisting of near identical 34
amino-acid modules that bind one nucleotide with high affin-
ity. The variable 12th and 13th amino-acids of TALs, called
repeat-variable di-nucleotide confers base specificity (NN→G/A,
NI→A, NG→T, NK→G, HD→C, and NS→A/T/C/G) and
TAL arrays that target a nucleotide sequence can be generated
by assembling individual modules (17, 20). ZFPs are eukary-
otic DNA-binding proteins. Cys2-His2 fingers, which are used
for genome editing, are the most common ZFP motif (21) and
are each specific for a nucleotide triplet. Artificial ZFP domains
that target specific DNA sequences, usually 9–18 nt long, can be
constructed by assembling individual fingers (18). ZFPs and TALs
have similar modular configurations but TALs can in theory target
any stretch of nucleotides beginning with a thymidine whereas
some structural incompatibilities between individual ZFP mod-
ules due to overlapping DNA-binding domains make the assembly
FIGURE 1 | (A) Schematic diagram of the ZFN, TALEN, and CRISPR/Cas9
genome editing tools. (B) Inhibition of T-cell activation by immune checkpoint
receptors and downstream signaling proteins. Several co-inhibitory receptors
(PD-1, BTLA, and LAIR-1) inhibit T-cell signaling by recruiting the SHP-1 and/or
SHP-2 tyrosine phosphatases at proximity of the TCR signaling complex via
ITIMs and ITSMs. This results in the dephosphorylation of proximal kinases
downstream of TCR triggering. In addition PD-1 ligation was shown to induce
increased expression of the Cbl-b E3 ubiquitin ligase, which targets signaling
molecules for degradation. Activation of the CD200R leads to the recruitment
of DOK2 and RasGAP to its intra-cellular domain, resulting in the inhibition of
downstream MAP kinases. The adenosine receptor 2A and PGE2 receptors
EP2 and EP4 modulate T-cell activation through mobilization of the
cAMP-PKAI-CSK pathway. CSK phosphorylates the inhibitory C-terminal
tyrosine residue of Src kinases and negatively regulates TCR signaling. A2AR,
adenosine A2a receptor; APC, antigen-presenting cell; BTLA-4, B- and
T-lymphocyte attenuator; Cbl-b, casitas B-cell lymphoma; CTL, cytotoxic
T-lymphocyte; DOK-1/2, docking protein 1/2; EP2/4, prostaglandin E receptor
2/4; Erk, extra-cellular signal regulated kinases; ITIM, immunoreceptor
tyrosine-based inhibition motif; ITSM, immunoreceptor tyrosine-based switch
motif; GPCR, G-protein coupled receptor; LAG-3, lymphocyte-activation gene
3; LAIR-1, leukocyte-associated immunoglobulin-like receptor 1; Lck,
lymphocyte-specific protein tyrosine kinase; MHC1, major histocompatibility
complex class 1; PD-1, programed death receptor 1; PD1-L1, programed death
receptor 1-ligand 1; SHP-1, Src homology 2 domain containing protein tyrosine
phosphatase; TCR, T-cell receptor; TIGIT, T-cell immunoreceptor with Ig and
ITIM domains; TIM-3, T-cell immunoglobulin domain and mucin domain 3.
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of oligomeric ZFPs error-prone and narrow down the diversity of
possible target DNA sequences. A successful and popular applica-
tion of these technologies is the fusion of customized ZFPs or TALs
to the catalytic domain of the restriction nuclease Fok1 (ZFNs
and TALENs). Fok1 nucleases catalyze DNA double strand breaks
(DSBs) when they dimerize (22). TALENs and ZFNs are there-
fore designed in pairs that target adjacent sequences on opposite
DNA strands, thereby promoting Fok1 dimerization, separated by
a spacer region where DNA cleavage occurs. Non-homologous end
joining (NHEJ) repair of DSBs results in insertions or deletions at
the DNA cleavage site (17, 23) and bi-allelic frameshift mutations
that result in complete knockout occur at low frequencies (18,
24). The overall efficiency of the approach is sufficient to gener-
ate knockout cells following appropriate selection procedures. Of
note TALEN design is more flexible as they can accommodate
spacers of different lengths (25) whereas ZFNs strictly require
5–7 nt (26). Taking this into account, as well as structural con-
straints mentioned above, it is estimated that the frequency of
target sequences is 1 in 500 bp for ZFNs and 1 in 35 bp for
TALENs (20).
RNA-guided endonucleases provide a distinct and attractive
alternative to genome editing compared with protein-guided
nucleases. The functions of clustered regularly interspaced short
palindromic repeats (CRISPR) and CRISPR-associated (Cas) pro-
teins as a system providing adaptive immunity to bacteria against
bacteriophages (27, 28) was recently harnessed for genome engi-
neering (29, 30). The Cas9 nuclease binds to a short complemen-
tary RNA (crRNA) providing DNA-targeting specificity and to a
trans-activating crRNA (tracRNA), required for crRNA process-
ing, expressed individually or combined as a chimeric guide RNA
(gRNA) (Figure 1A). CRISPR-Cas9 systems displayed a cleavage
efficiency comparable (31) or superior (32) to TALENs in human
cells. The clear advantage of RGEN is that it can be easily adapted
to target different genomic sequences by customizing the syn-
thetic crRNA/gRNA delivered in combination with Cas9 (33). In
comparison ZFNs and TALENs require extensive engineering and
validation steps.
The delivery of genome editing agents to T-cells is a crucial
aspect of their successful application to ACTs. Because nuclease-
based genome editing relies on generating transmissible muta-
tions, protein- or RNA-guided nucleases only need to be tran-
siently expressed. In fact transient expression probably minimizes
off-target DNA cleavage (34). Provasi et al. have used integration-
deficient lentiviruses as well as adenoviruses in order to modify the
genome of T-cells with ZFNs (35). Of note it was recently shown
that, due to their very repetitive nature, TAL arrays were incompat-
ible with efficient reverse transcription required for the delivery of
genetic material using lentiviruses (36), thereby limiting the range
of delivery methods for TALENs.
APPLICATION OF THERAPEUTIC GENOME EDITING TO T-CELLS
Crucially therapies based on T-cell genome editing have already
entered clinical development. A phase II clinical trial based on
preventing the expression of the CCR5 gene,acting as a co-receptor
for HIV in CD4+ T-cells, using ZFNs (37) was recently initiated
for the treatment of HIV/AIDS (NCT01252641). The safety results
will be of huge importance for ZFN-based therapies and for
genome editing in T-cells in general. Moreover a recent study pro-
vided proof of concept for the combination of TCR gene delivery
with genome editing by using ZFNs specific for the endogenous
constant TCR gene segments in order to prevent mispairing with
ectopic TCR chains (35). The success of this approach provides a
good rationale for wider applications of ZFN genome editing to
T-cells.
Enhancing the anti-tumor potential of CD8+ T-cells through
genome editing can be done in many ways. Here we will focus
on disrupting the expression of genes that inhibit T-cell func-
tions as a result of the suppressive activity of the tumor micro-
environment. T-cell inhibitory pathways targeted by genome edit-
ing in the context cancer ACTs should meet several criteria. First,
their mechanism of action should be strictly cell-intrinsic. Sec-
ond, they should be relevant to effector T-cells as opposed to
naive T-cells. For instance CTLA-4 does not meet these two crite-
ria since it works at least partly by reducing the availability of
co-stimulatory molecules on the surface of antigen-presenting
cells during the priming of naive T-cells (38). Finally, since only
anti-tumor T-cells are modified, one of the advantages of this
approach is that it allows targeting ubiquitous suppressive path-
ways whose systemic blockade or inhibition might result in serious
adverse effects. Because it is clinically validated the most obvious
target is probably PDCD1: the gene encoding the co-inhibitory
receptor PD-1. PD-1 is expressed on activated T-cells and its
engagement by its two known ligands PD-L1 and PD-L2 inhibits
proximal signaling events triggered by TCR stimulation through
recruitment of the phosphatase SHP-2 (39) and increased expres-
sion of the E3 ubiquitin ligase Cbl-b (40), which impair key
components of the TCR signaling cascade through dephospho-
rylation and proteasomal degradation (Figure 1B). High cellular
expression levels of PD-1 are characteristic of exhausted CD8+
T-cells in chronic viral infections as well as TILs and corre-
late with impaired effector functions (41). Histological analyses
have revealed that numerous tumor types express one or both
PD-1 ligands (42, 43), prompting the targeting of this pathway
in order to augment anti-tumor immunity. PD-1 blockade has
shown promising objective response rates in a range of cancer
indications and it is anticipated that PD-1 blocking agents will
be approved for marketing authorization as mono-therapies. In
addition these therapeutics are evaluated in combination with can-
cer vaccines, small-molecule signaling inhibitors, tumor-targeting
mAbs, and cytokine therapy (http://clinicaltrials.gov/ct2/results?
term=pd1&Search=Search). The combination of PD-1 blockade
with these treatments, as well as with cancer ACTs, is expected
to further enhance anti-tumor activity (11). Several other co-
inhibitory receptors expressed by T-cells qualify as targets for
gene editing coupled with antigen receptor delivery (Table 1;
Figure 1B). In vivo and in vitro pre-clinical data strongly support
the development of reagents targeting TIM-3 and LAG-3. Dual
targeting of PD-1 and TIM-3 or LAG-3 with mAbs synergistically
enhanced anti-tumor responses (44) and pre-clinical evaluations
of a soluble Fc-LAG3 complex, which has now entered clinical
development, were promising (45). Other targets are currently
under similar evaluation procedures and might expand the list
of druggable co-inhibitory receptors for cancer immunotherapy
(Table 1; Figure 1B).
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Table 1 | Potential immune checkpoint receptor targets for genome editing in the context of cancer adoptive cellular therapies.
Name (gene) Function Ligand Intra-cellular
signaling/second
messengers
Recognition
motif
References
Co-inhibitory
receptors
PD-1 (CD279) Inhibition of T-cell activation and
promotion of tolerance
PD-L1 (B7-H1) SHP-1 ITIM Keir et al. (56), Parry et
al. (57)PD-L2 (B7-DC) SHP-2 ITSM
LAG-3 (CD223) Down regulation of T-cell cytokine
secretion and proliferation
MHCII – – Pardoll (12), Turnis et al.
(58)
BTLA (CD272) Suppression of T-cell response HVEM SHP-2 ITIM Murphy et al. (59),
Watanabe et al. (60)
OX2R (CD200R) Inhibits T-cell function CD200 DOK2 NPxY Kretz-Rommel et al.
(61), Moreaux et al.
(62), Pallasch et al. (63)
TIM-3 Down regulation of T-cell cytokine
secretion and proliferation
Galectin 9 – – Pardoll (12), Zhu et al.
(64)Phosphatidylserine
TIGIT Inhibition of T-cell activation VR, PVRL2, and
PVRL3
– ITIM Joller et al. (65)
LAIR-1 Inhibits cytotoxic activity Collagen SHP-1 ITIM Lebbink et al. (66),
Meyaard (67)SHP-2
Receptors for
soluble
regulatory
mediators
PGE2 receptors
EP2/4
Inhibition of T-cell activity PGE2 Adenylyl cyclase – Mahic et al. (68),
Oberprieler et al. (53)cAMP
Adenosine
receptor 2A
(A2AR)
Blocks T-cell activity Adenosine Adenylyl cyclase
cAMP
– Pardoll (12), Ohta et al.
(50), Raskovalova et al.
(69)
Non-extensive list of immune checkpoint receptors known to impair anti-tumorT-cell immunity in a cell-intrinsic manner.The relevant intra-cellular signaling and second
messenger pathways, when known, are indicated.
The presence of cognate ligands within the tumor micro-
environment is a crucial aspect for targeting co-inhibitory recep-
tors and other immune checkpoint receptors. In the case of PD-1
retrospective analysis of patient biopsies in the phase Ib clinical
trial assessing the blocking mAb BMS-936558 showed that the
objective response rate in patients whose tumors expressed PD-L1
reached 36% compared with 18% in the entire cohort and 0%
among patients with PD-L1-negative tumors (46). These striking
results highlight the importance of prognosis and patient strat-
ification for the design of appropriate cancer immunotherapies
based on PD-1 inhibition. Such a strong correlation is still to be
established for other immune checkpoint receptors but it is tempt-
ing to speculate that similar principles are applicable. However,
even though their relevance in tumor immunity is established,
it is not entirely clear what the actual ligands for several co-
inhibitory receptors are in the context of anti-tumor immunity.
More fundamental and clinical investigations are required in order
to unambiguously identify relevant inhibitory ligands and assess
their presence in the tumor environment.
Several soluble regulatory mediators also act as immune check-
points in anti-tumor immunity. For instance high levels of extra-
cellular adenosine are found in the vicinity of many solid tumors
because of the hypoxic environment, a well-known environmen-
tal factor promoting adenosine release. Suppressive adenosine
is also generated through direct dephosphorylation of extra-
cellular adenosine nucleotides by the cell-surface nucleotidases
CD39 and CD73 expressed by regulatory T-cells (Tregs) and some
tumors, e.g., ovarian carcinomas (47, 48). The adenosine receptor
2A (A2AR), belonging to the G-protein coupled receptor family
(GPCRs), is expressed on T-cells and has been identified as a target
for immunotherapy for over a decade (12, 49–51). The A2AR
inhibits T-cell activation through the cAMP-PKAI-CSK pathway
(Figure 1B) and pre-clinical in vivo models have shown that
A2AR knock-down or antagonism in adoptively transferred T-
cells dramatically increased anti-tumor immunity (50). Inhibiting
adenosine-mediated immune suppression is therefore believed to
be an efficient strategy for cancer immunotherapies. Yet because
adenosine receptors are ubiquitously expressed and involved in
many physiological processes, especially in neurotransmission,
classical antagonistic approaches are likely to result in a number of
side effects. Such systemic adverse effects could be avoided in the
context of adoptive T-cell therapies through T-cell-intrinsic gene
editing or the in vitro selection of desensitized and irresponsive T-
cells (52). Similarly, prostaglandin E2 (PGE2) directly suppresses
T-cell activation through the cAMP second messenger pathway
in effector/memory CD8+ T-cells (53). Tumor-associated Tregs as
well as colorectal cancer cells express high levels of immunosup-
pressive PGE2 (54). Interfering with EP2/EP4 receptors expression
in T-cells may therefore enhance their anti-tumor potential.
A broader, possibly riskier, alternative to targeting individ-
ual immune checkpoint receptors would be interfering with
the expression of downstream molecules conveying intra-cellular
inhibitory signals. For instance several co-inhibitory receptors use
the tyrosine phosphatases SHP-1 and/or SHP-2 to inhibit T-cell
activation (Figure 1B). Inhibition of SHP-1/2 expression may
therefore confer resistance to several checkpoint pathways used by
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tumors. Stromnes and colleagues reported that conditional knock-
out of SHP-1 in mature murine CD8+ T-cells improved effector
cell functions and tumor clearance in an adoptive transfer setting
similar to cancer ACTs without resulting in autoimmune toxicity,
thereby providing a good rationale for such an approach (55).
CONCLUDING REMARKS
T-cell based ACTs that rely on the re-infusion of patient T-cells
expressing an artificial antigen receptor is an epitome of personal-
ized medicine. These therapies require the identification of specific
tumor antigens and/or patient HLA-type and would undoubtedly
benefit from further prognostic analysis and subsequent treatment
customization. Based on recent successes in cancer immunother-
apy, immune checkpoint receptors that suppress T-cells represent
a particularly attractive class of targets for such an approach. We
believe that enhancing the anti-tumor potential of re-directed T-
cells by targeting inhibitory pathways through genome editing
can further improve the efficacy of cancer ACTs. Moreover cell-
intrinsic inhibition of these pathways may display an advantageous
safety profile compared with immune checkpoint blockade relying
on the systemic administration of mAbs, recombinant proteins, or
small molecules.
The field of genome editing is currently buzzing with new ideas
and technologies that make the application of targeted gene knock-
out and gene correction a tantalizing prospect for the development
of customized ACTs in regenerative medicine and immunother-
apy. However, numerous potential pitfalls must be assessed in pre-
clinical development. At this point ZFNs are the most advanced
technology for genome editing and have already entered clini-
cal development. However, their complicated and labor-intensive
design, construction, and validation are major drawbacks for their
widespread use in non-specialized laboratories, which often rely
on commercial reagents. TALENs, on the other hand, are much
more user-friendly and several toolboxes that allow investigators
to generate custom reagents are available at low cost. With regard
to T-cell based cancer ACTs, however, the incompatibility of TAL-
ENs with retroviral delivery, often used to express ectopic TCRs or
CARs, might be problematic. Finally, CRISPR-Cas9 genome edit-
ing may prove to be the holy grail of genome editing but the current
lack of hindsight on this technology does not allow concluding on
its use yet. Thorough assessment of the respective advantages and
drawbacks of each technology as well as pre-clinical feasibility and
safety studies are warranted to validate genome editing applied to
cancer ACTs.
REFERENCES
1. Schreiber RD, Old LJ, Smyth MJ.
Cancer immunoediting: integrat-
ing immunity’s roles in. Science
(2011) 331(6024):1565–70. doi:10.
1126/science.1203486
2. Mellman I, Coukos G, Dranoff G.
Cancer immunotherapy comes of
age. Nature (2011) 480:480–9. doi:
10.1038/nature10673
3. Klebanoff CA, Acquavella N, Yu Z,
Restifo NP. Therapeutic cancer vac-
cines: are we there yet? Immunol
Rev (2011) 239:27–44. doi:10.1111/
j.1600-065X.2010.00979.x
4. Porter DL, Levine BL, Kalos M,
Bagg A, June CH. Chimeric antigen
receptor-modified T cells in chronic
lymphoid leukemia. N Engl J Med
(2011) 365:725–33. doi:10.1056/
NEJMoa1103849
5. Robbins PF, Morgan RA, Feldman
SA, Yang JC, Sherry RM, Dud-
ley ME, et al. Tumor regression
in patients with metastatic syn-
ovial cell sarcoma and melanoma
using genetically engineered lym-
phocytes reactive with NY-ESO-1. J
Clin Oncol (2011) 29:917–24. doi:
10.1200/JCO.2010.32.2537
6. Rosenberg SA, Yang JC, Sherry
RM, Kammula US, Hughes MS,
Phan GQ, et al. Durable com-
plete responses in heavily pre-
treated patients with metasta-
tic melanoma using T-cell trans-
fer immunotherapy. Clin Cancer
Res (2011) 17:4550–7. doi:10.1158/
1078-0432.CCR-11-0116
7. Blank CU, Hooijkaas AI, Haa-
nen JB, Schumacher TN.
Combination of targeted ther-
apy and immunotherapy in
melanoma. Cancer Immunol
Immunother (2011) 60:1359–71.
doi:10.1007/s00262-011-1079-2
8. Vanneman M, Dranoff G. Combin-
ing immunotherapy and targeted
therapies in cancer treatment. Nat
Rev Cancer (2012) 12:237–51. doi:
10.1038/nrc3237
9. Noh KH, Kang TH, Kim JH, Pai
SI, Lin KY, Hung CF, et al. Acti-
vation of Akt as a mechanism for
tumor immune evasion. Mol Ther
(2009) 17:439–47. doi:10.1038/mt.
2008.255
10. Boni A, Cogdill AP, Dang P,
Udayakumar D, Njauw CN, Sloss
CM, et al. Selective BRAFV600E
inhibition enhances T-cell recogni-
tion of melanoma without affect-
ing lymphocyte function. Cancer
Res (2010) 70:5213–9. doi:10.1158/
0008-5472.CAN-10-0118
11. Martinez Forero I, Okada H,
Topalian SL, Gajewski TF, Kor-
man AJ, Melero I. Workshop
on immunotherapy combinations.
Society for immunotherapy of
cancer annual meeting Bethesda,
November 3, 2011. J Transl Med
(2012) 10:108. doi:10.1186/1479-
5876-10-108
12. Pardoll DM. The blockade of
immune checkpoints in cancer
immunotherapy. Nat Rev Can-
cer (2012) 12:252–64. doi:10.1038/
nrc3239
13. An DS, Qin FX, Auyeung VC,
Mao SH, Kung SK, Baltimore D,
et al. Optimization and functional
effects of stable short hairpin
RNA expression in primary
human lymphocytes via lentiviral
vectors. Mol Ther (2006) 14:494–
504. doi:10.1016/j.ymthe.2006.05.
015
14. Yi R, Doehle BP, Qin Y, Macara
IG, Cullen BR. Overexpression of
exportin 5 enhances RNA inter-
ference mediated by short hairpin
RNAs and microRNAs. RNA (2005)
11:220–6. doi:10.1261/rna.7233305
15. Castanotto D, Sakurai K, Linge-
man R, Li H, Shively L, Aagaard
L, et al. Combinatorial delivery
of small interfering RNAs reduces
RNAi efficacy by selective incorpo-
ration into RISC. Nucleic Acids Res
(2007) 35:5154–64. doi:10.1093/
nar/gkm543
16. Couto LB, High KA. Viral vector-
mediated RNA interference. Curr
Opin Pharmacol (2010) 10:534–42.
doi:10.1016/j.coph.2010.06.007
17. Sanjana NE, Cong L, Zhou Y, Cun-
niff MM, Feng G, Zhang F. A
transcription activator-like effector
toolbox for genome engineering.
Nat Protoc (2012) 7:171–92. doi:10.
1038/nprot.2011.431
18. Urnov FD, Rebar EJ, Holmes MC,
Zhang HS, Gregory PD. Genome
editing with engineered zinc fin-
ger nucleases. Nat Rev Genet (2010)
11:636–46. doi:10.1038/nrg2842
19. Hwang WY, Fu Y, Reyon D, Maeder
ML, Tsai SQ, Sander JD, et al. Effi-
cient genome editing in zebrafish
using a CRISPR-Cas system. Nat
Biotechnol (2013) 31:227–9. doi:10.
1038/nbt.2501
20. Cermak T, Doyle EL, Christian
M, Wang L, Zhang Y, Schmidt
C, et al. Efficient design and
assembly of custom TALEN and
other TAL effector-based constructs
for DNA targeting. Nucleic Acids
Res (2011) 39:e82. doi:10.1093/nar/
gkr218
21. Wolfe SA, Nekludova L, Pabo CO.
DNA recognition by Cys2His2 zinc
finger proteins. Annu Rev Bio-
phys Biomol Struct (2000) 29:183–
212. doi:10.1146/annurev.biophys.
29.1.183
22. Hockemeyer D, Soldner F, Beard C,
Gao Q, Mitalipova M, DeKelver
RC, et al. Efficient targeting
of expressed and silent genes in
human ESCs and iPSCs using zinc-
finger nucleases. Nat Biotechnol
(2009) 27:851–7. doi:10.1038/nbt.
1562
23. Kim Y, Kweon J, Kim A, Chon JK,
Yoo JY, Kim HJH, et al. A library
of TAL effector nucleases spanning
the human genome. Nat Biotech-
nol (2013) 31:251–8. doi:10.1038/
nbt.2517
24. Urnov FD, Miller JC, Lee YL,
Beausejour CM, Rock JM, Augus-
tus S, et al. Highly efficient
endogenous human gene correction
using designed zinc-finger nucle-
ases. Nature (2005) 435:646–51.
doi:10.1038/nature03556
25. Miller JC, Tan S, Qiao G, Bar-
low KA, Wang J, Xia DF, et al. A
TALE nuclease architecture for effi-
cient genome editing. Nat Biotech-
nol (2011) 29:143–8. doi:10.1038/
nbt.1755
www.frontiersin.org August 2013 | Volume 4 | Article 221 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lloyd et al. New tools for cellular immunotherapies
26. Christian M, Cermak T, Doyle EL,
Schmidt C, Zhang F, Hummel A,
et al. Targeting DNA double-strand
breaks with TAL effector nucleases.
Genetics (2010) 186:757–61. doi:10.
1534/genetics.110.120717
27. Brouns SJ, Jore MM, Lundgren M,
Westra ER, Slijkhuis RJ, Snijders AP,
et al. Small CRISPR RNAs guide
antiviral defense in prokaryotes. Sci-
ence (2008) 321:960–4. doi:10.1126/
science.1159689
28. Jinek M, Chylinski K, Fonfara I,
Hauer M, Doudna JA, Charp-
entier E. A programmable dual-
RNA-guided DNA endonuclease in
adaptive bacterial immunity. Sci-
ence (2012) 337:816–21. doi:10.
1126/science.1225829
29. Cong L, Ran FA, Cox D, Lin
S, Barretto R, Habib N, et al.
Multiplex genome engineer-
ing using CRISPR/Cas sys-
tems. Science (2013) 339:819–23.
doi:10.1126/science.1231143
30. Mali P, Yang L, Esvelt KM, Aach J,
Guell M, DiCarlo JE, et al. RNA-
guided human genome engineering
via Cas9. Science (2013) 339:823–6.
doi:10.1126/science.1232033
31. Habib N, Hsu PD, Wu X, Jiang
W, Luciano A, Cong L, et al.
Multiplex genome engineer-
ing using CRISPR/Cas sys-
tems. Science (2013) 339:819–23.
doi:10.1126/science.1231143
32. Ding Q, Regan SN, Xia Y, Oost-
rom LA, Cowan CA, Musunuru
K. Enhanced efficiency of human
pluripotent stem cell genome edit-
ing through replacing TALENs with
CRISPRs. Cell Stem Cell (2013)
12:393–4. doi:10.1016/j.stem.2013.
03.006
33. van der Oost J. Molecular biol-
ogy. New tool for genome surgery.
Science (2013) 339:768–70. doi:10.
1126/science.1234726
34. Lombardo A, Genovese P, Beause-
jour CM, Colleoni S, Lee YL, Kim
KA, et al. Gene editing in human
stem cells using zinc finger nucle-
ases and integrase-defective lentivi-
ral vector delivery. Nat Biotechnol
(2007) 25:1298–306. doi:10.1038/
nbt1353
35. Provasi E, Genovese P, Lombardo
A, Magnani Z, Liu PQ, Reik A, et
al. Editing T cell specificity towards
leukemia by zinc finger nucleases
and lentiviral gene transfer. Nat Med
(2012) 18:807–15. doi:10.1038/nm.
2700
36. Holkers M, Maggio I, Liu J, Janssen
JM, Miselli F, Mussolino C, et
al. Differential integrity of TALE
nuclease genes following adenoviral
and lentiviral vector gene transfer
into human cells. Nucleic Acids Res
(2012) 41(5):e63. doi:10.1093/nar/
gks1446
37. Perez EE, Wang J, Miller JC, Jou-
venot Y, Kim KA, Liu O, et al.
Establishment of HIV-1 resistance
in CD4+ T cells by genome edit-
ing using zinc-finger nucleases. Nat
Biotechnol (2008) 26:808–16. doi:
10.1038/nbt1410
38. Qureshi OS, Zheng Y, Nakamura
K, Attridge K, Manzotti C, Schmidt
EM, et al. Trans-endocytosis of
CD80 and CD86: a molecular basis
for the cell-extrinsic function of
CTLA-4. Science (2011) 332:600–3.
doi:10.1126/science.1202947
39. Freeman GJ, Long AJ, Iwai Y,
Bourque K, Chernova T, Nishimura
H, et al. Engagement of the PD-
1 immunoinhibitory receptor by
a novel B7 family member leads
to negative regulation of lympho-
cyte activation. J Exp Med (2000)
192:1027–34. doi:10.1084/jem.192.
7.1027
40. Karwacz K, Bricogne C, Mac-
donald D, Arce F, Bennett CL,
Collins M, et al. PD-L1 co-
stimulation contributes to ligand-
induced T cell receptor down-
modulation on CD8+ T cells.
EMBO Mol Med (2011) 3:581–92.
doi:10.1002/emmm.201100165
41. Wherry EJ. T cell exhaustion. Nat
Immunol (2011) 12:492–9. doi:10.
1038/ni.2035
42. Topalian SL, Drake CG, Pardoll DM.
Targeting the PD-1/B7-H1(PD-L1)
pathway to activate anti-tumor
immunity. Curr Opin Immunol
(2012) 24:207–12. doi:10.1016/j.
coi.2011.12.009
43. Zitvogel L, Kroemer G. Targeting
PD-1/PD-L1 interactions for can-
cer immunotherapy. Oncoimmunol-
ogy (2012) 1:1223–5. doi:10.4161/
onci.21335
44. Woo SR, Turnis ME, Goldberg MV,
Bankoti J, Selby M, Nirschl CJ, et al.
Immune inhibitory molecules LAG-
3 and PD-1 synergistically regulate
T-cell function to promote tumoral
immune escape. Cancer Res (2012)
72:917–27. doi:10.1158/0008-5472.
CAN-11-1620
45. Fougeray S, Brignone C, Triebel
F. A soluble LAG-3 protein as
an immunopotentiator for thera-
peutic vaccines: preclinical evalu-
ation of IMP321. Vaccine (2006)
24:5426–33. doi:10.1016/j.vaccine.
2006.03.050
46. Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDer-
mott DF, et al. Safety, activity, and
immune correlates of anti-PD-1
antibody in cancer. N Engl J Med
(2012) 366:2443–54. doi:10.1056/
NEJMoa1200690
47. Jin D, Fan J, Wang L, Thompson
LF, Liu A, Daniel BJ, et al. CD73
on tumor cells impairs antitumor
T-cell responses: a novel mecha-
nism of tumor-induced immune
suppression. Cancer Res (2010)
70:2245–55. doi:10.1158/0008-
5472.CAN-09-3109
48. Häusler SF, Montalbán del Barrio
I, Strohschein J, Anoop Chan-
dran P, Engel JB, Hönig A, et
al. Ectonucleotidases CD39 and
CD73 on OvCA cells are potent
adenosine-generating enzymes
responsible for adenosine recep-
tor 2A-dependent suppression
of T cell function and NK cell
cytotoxicity. Cancer Immunol
Immunother (2011) 60:1405–18.
doi:10.1007/s00262-011-1040-4
49. Ohta A, Sitkovsky M. Role of G-
protein-coupled adenosine recep-
tors in downregulation of inflam-
mation and protection from tissue
damage. Nature (2001) 414:916–20.
doi:10.1038/414916a
50. Ohta A, Gorelik E, Prasad SJ,
Ronchese F, Lukashev D, Wong
MKK, et al. A2A adenosine recep-
tor protects tumors from antitu-
mor T cells. Proc Natl Acad Sci
USA (2006) 103:13132–7. doi:10.
1073/pnas.0605251103
51. Sitkovsky M, Ohta A. Targeting
the hypoxia-adenosinergic signal-
ing pathway to improve the adop-
tive immunotherapy of cancer. J
Mol Med (Berl) (2013) 91:147–55.
doi:10.1007/s00109-013-1001-9
52. Ohta A, Kjaergaard J, Sharma
S, Mohsin M, Goel N, Madasu
M, et al. In vitro induction
of T cells that are resistant to
A2 adenosine receptor-mediated
immunosuppression. Br J Phar-
macol (2009) 156:297–306. doi:10.
1111/j.1476-5381.2008.00019.x
53. Oberprieler NG, Lemeer S, Kalland
ME, Torgersen KM, Heck AJ, Tasken
K. High-resolution mapping of
prostaglandin E2-dependent signal-
ing networks identifies a constitu-
tively active PKA signaling node
in CD8+CD45RO+ T cells. Blood
(2010) 116:2253–65. doi:10.1182/
blood-2010-01-266650
54. Mosenden R, Tasken K. Cyclic
AMP-mediated immune regula-
tion – overview of mechanisms
of action in T cells. Cell Signal
(2011) 23:1009–16. doi:10.1016/j.
cellsig.2010.11.018
55. Stromnes IM, Fowler C, Casamina
CC, Georgopolos CM, McAfee
MS, Schmitt TM, et al. Abroga-
tion of SRC homology region
2 domain-containing phos-
phatase 1 in tumor-specific T
cells improves efficacy of adoptive
immunotherapy by enhancing the
effector function and accumulation
of short-lived effector T cells
in vivo. J Immunol (2012) 189:
1812–25. doi:10.4049/jimmunol.
1200552
56. Keir ME, Butte MJ, Freeman GJ,
Sharpe AH. PD-1 and its lig-
ands in tolerance and immu-
nity. Annu Rev Immunol (2008)
26:677–704. doi:10.1146/annurev.
immunol.26.021607.090331
57. Parry RV, Chemnitz JM, Frauwirth
KA, Lanfranco AR, Braunstein
I, Kobayashi SV, et al. CTLA-4
and PD-1 receptors inhibit T-cell
activation by distinct mechanisms.
Mol Cell Biol (2005) 25:9543–
53. doi:10.1128/MCB.25.21.9543-
9553.2005
58. Turnis ME, Korman AJ, Drake
CG, Vignali DA. Combinatorial
immunotherapy: PD-1 may not be
LAG-ing behind any more. Oncoim-
munology (2012) 1:1172–4. doi:10.
4161/onci.20593
59. Murphy KM, Nelson CA, Sedý JR.
Balancing co-stimulation and inhi-
bition with BTLA and HVEM. Nat
Rev Immunol (2006) 6:671–81. doi:
10.1038/nri1917
60. Watanabe N, Gavrieli M, Sedy JR,
Yang J, Fallarino F, Loftin SK, et al.
BTLA is a lymphocyte inhibitory
receptor with similarities to CTLA-
4 and PD-1. Nat Immunol (2003)
4:670–9. doi:10.1038/ni944
61. Kretz-Rommel A, Qin F, Dakap-
pagari N, Ravey EP, McWhirter J,
Oltean D, et al. CD200 expression
on tumor cells suppresses antitumor
immunity: new approaches to can-
cer immunotherapy. Mian Yi Xue Za
Zhi (2007) 178:5595–605.
62. Moreaux J, Veyrune JL, Reme T,
De Vos J, Klein B. CD200: a
putative therapeutic target in can-
cer. Biochem Biophys Res Commun
(2008) 366:117–22. doi:10.1016/j.
bbrc.2007.11.103
63. Pallasch CP, Ulbrich S, Brinker
R, Hallek M, Uger RA, Wendtner
C-M. Disruption of T cell sup-
pression in chronic lymphocytic
leukemia by CD200 blockade. Leuk
Res (2009) 33:460–4. doi:10.1016/j.
leukres.2008.08.021
64. Zhu C, Anderson AC, Schubart A,
Xiong H, Imitola J, Khoury SJ,
et al. The Tim-3 ligand galectin-9
negatively regulates T helper type
1 immunity. Nat Immunol (2005)
6:1245–52. doi:10.1038/ni1271
65. Joller N, Hafler JP, Brynedal
B, Kassam N, Spoerl S, Levin
Frontiers in Immunology | T Cell Biology August 2013 | Volume 4 | Article 221 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lloyd et al. New tools for cellular immunotherapies
SD, et al. Cutting edge: TIGIT
has T cell-intrinsic inhibitory
functions. Mian Yi Xue Za
Zhi (2011) 186:1338–42.
doi:10.4049/jimmunol.1003081
66. Lebbink RJ, de Ruiter T, Adelmeijer
J, Brenkman AB, van Helvoort
JM, Koch M, et al. Collagens are
functional, high affinity ligands
for the inhibitory immune recep-
tor LAIR-1. J Exp Med (2006)
203:1419–25. doi:10.1084/jem.
20052554
67. Meyaard L. The inhibitory colla-
gen receptor LAIR-1 (CD305). J
Leukoc Biol (2008) 83:799–803. doi:
10.1189/jlb.0907609
68. Mahic M, Yaqub S, Johansson
CC, Taskén K, Aandahl EM.
FOXP3+CD4+CD25+ adap-
tive regulatory T cells express
cyclooxygenase-2 and suppress
effector T cells by a prostaglandin
E2-dependent mechanism.
Mian Yi Xue Za Zhi (2006)
177:246–54.
69. Raskovalova T, Lokshin A, Huang
X, Su Y, Mandic M, Zarour HM,
et al. Inhibition of cytokine pro-
duction and cytotoxic activity of
human antimelanoma specific
CD8+ and CD4+ T lymphocytes
by adenosine-protein kinase A
type I signaling. Cancer Res (2007)
67:5949–56. doi:10.1158/0008-
5472.CAN-06-4249
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 18 April 2013; accepted: 16 July
2013; published online: 05 August 2013.
Citation: Lloyd A, Vickery ON and
Laugel B (2013) Beyond the antigen
receptor: editing the genome of T-
cells for cancer adoptive cellular
therapies. Front. Immunol. 4:221. doi:
10.3389/fimmu.2013.00221
This article was submitted to Frontiers in
T Cell Biology, a specialty of Frontiers in
Immunology.
Copyright © 2013 Lloyd, Vickery and
Laugel. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) or licensor are cred-
ited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use, dis-
tribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org August 2013 | Volume 4 | Article 221 | 7
